Advertisement
Advertisement
PBLS
Parabilis Medicines, Inc. Common Stock
39.11
USDSponsored
-0.18
-0.46%
Aug 28, 16:00 UTC -4
Closed
After-Market
39.09
-0.02
-0.05%
PBLS Earnings Reports
Positive Surprise Ratio
PBLS beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Parabilis Medicines, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, PBLS reported earnings of -2.12 USD per share (EPS) for Q2 26, missing the estimate of 0.08 USD, resulting in a -2698.04% surprise. Revenue reached 148.00 thousand, compared to an expected 25.50 million, with a -99.42% difference. The market reacted with a -4.65% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
FAQ
What were Parabilis Medicines, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Parabilis Medicines, Inc. Common Stock reported EPS of -$2.12, missing estimates by -2698.04%, and revenue of $148.00K, -99.42% below expectations.
How did the market react to Parabilis Medicines, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -4.65%, changed from $37.41 before the earnings release to $35.67 the day after.
When is Parabilis Medicines, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Parabilis Medicines, Inc. Common Stock's next earnings report?
Based on --
analysts, Parabilis Medicines, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement